Premium
Synthesis of [ 195m Pt]‐tetraplatin
Author(s) -
Wyrick Steven D.,
Chaney Stephen G.
Publication year - 1990
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.2580280703
Subject(s) - chemistry , in vivo , cisplatin , moiety , platinum , stereochemistry , organic chemistry , catalysis , chemotherapy , surgery , medicine , microbiology and biotechnology , biology
(Trans d,1)‐1,2‐diaminocyclohexanetetrachloroplatinum(IV) (tetraplatin) is a second generation platinum antitumor agent which exhibits less toxicity than cisplatin and is effective in cell lines with acquired resistance to cisplatin. We previously reported the synthesis of tritium labelled tetraplatin which was utilized in both tissue culture and in vivo studies. Loss of the labelled diaminocyclohexane carrier moiety during the in vivo studies necessitated the synthesis of [ 195m Pt]‐tetraplatin from [ 195m Pt]‐potassium hexachloroplatinate as described herein.